Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 95. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Adaora “Ada” Alise Adimora1515
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis1227
Highlights from the sixth ESCMID Conference on Vaccines1016
DNDi receives Dutch funding boost567
HIV vaccine trial failure549
Research in brief481
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum438
COVID-19 vaccination protects children and adolescents414
A patient with secondary syphilis following incomplete treatment of primary infection372
Environment and infectious diseases365
Promoting diversity and equity in publishing344
A step forward in the journey towards hookworm vaccines306
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7292
Listeria monocytogenes: a rare, deadly cause of peritonitis285
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations279
Updated criteria for paediatric sepsis and septic shock277
Correction to Lancet Infect Dis 2025; 25: e280–93265
Infectious disease surveillance update257
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges253
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation252
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1241
Surge of cutaneous leishmaniasis in Pakistan240
Reflecting on lessons from the 2014–16 Ebola virus outbreak238
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations230
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis224
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco224
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria214
Measles immunity gaps and outbreak risk in a shifting landscape213
The next chapter for Africa's genomic initiatives205
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic201
The lasting lessons of mpox: infection, vaccination, and immune memory191
Attention to skin-related neglected tropical diseases185
Shaping opportunities for future clinical trials in tuberculosis182
Ivan Hirsch181
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting172
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden172
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C167
Threat of HIV and tuberculosis drug resistance after US funding cuts166
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial164
The superiority of bivalent over monovalent booster vaccines163
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children 159
Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, sing157
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect157
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study155
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study152
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review148
Kyasanur Forest disease: an emerging arboviral threat146
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom145
Best practice guidelines for viral hepatitis service delivery in prisons145
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial145
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer143
GoGoVax dispels hopes for gonorrhoea vaccination142
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial141
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial141
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study140
Mpox in people with past infection or a complete vaccination course: a global case series140
Research in brief139
Research in brief139
New flavours of tuberculosis treatment for children138
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents137
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site137
Global cholera resurgence—a preventable tragedy137
A new monoclonal in the arMAMentarium against malaria137
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study136
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia136
The implications of mpox breakthrough infections on future vaccination strategies135
Theresa Ochoa—staying on top of infectious diseases in Peru133
Research in brief128
RSV prevention: public health lessons from the southern hemisphere122
Tuberculosis recovery in Georgia: implementing more by 24121
Full-dose NSAIDs at the first sign of respiratory infection?121
Election of Regional Director for the Western Pacific119
Emil Gotschlich117
Supporting healthcare access for refugees and migrants116
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world114
Interplay of infection and vaccination in long-term protection from COVID-19114
Serpiginous-like choroiditis in ocular tuberculosis114
Correction to Lancet Infect Dis 2026; published online March 23. https://doi.org/10.1016/S1473-3099(26)00058-7113
Infectious disease surveillance update113
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86111
COVID-19 mortality in Africa and Asia – Authors' reply110
High-dose primaquine reduces vivax relapses: time for change108
Elisabeth Presterl—always looking forward107
The response of mpox-associated inflammatory syndrome to steroid therapy105
Research in brief105
Immune evasiveness of SARS-CoV-2 variants and vaccine selection104
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe102
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study101
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa99
Addressing the shortage of cholera vaccines99
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine98
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?98
Twin threats: climate change and zoonoses98
The global burden of cryptococcosis—a neglected tropical disease?96
Curing chronic hepatitis B virus infection95
0.26406502723694